Kura Oncology公司今日宣布,其在研疗法ziftomenib已经获得美国FDA授予的突破性疗法认定,用于治疗携带NPM1基因突变的复发/难治性急性髓系白血病(AML)患者。新闻稿指出,ziftomenib是首款针对这一患者群体获得突破性疗法认定的在研疗法。这款在研新药曾被猎药人网站(drughunter.com)列为2022年度10大“明星”小分子之一。
参考资料:[1] KURA ONCOLOGY RECEIVES BREAKTHROUGH THERAPY DESIGNATION FOR ZIFTOMENIB IN NPM1-MUTANT AML. Retrieved April 22, 2024, from https://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-receives-breakthrough-therapy-designation